More evidence to support the premise that #EBVcausesMS and that latent-lytic viral infection is driving the disease.
EBV-specific T-cell responses are telling us something very important about multiple sclerosis => https://buff.ly/4hbJTLe
EBV alters the transcriptome and immunopeptidome in HLA-DR15+ B cells, enhancing myelin peptide presentation, potentially driving MS pathogenesis. PMID:41534530, Cell 2026, @Cell www.cell.com/cell/fulltext/S0092-8674... #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
This provides further rationale for antiretroviral therapy to treat MS. More at art4ms.com
EBV Dysregulation Is Associated With Immune Imbalance in Multiple Sclerosis
www.neurology.org/doi/10.1212/...
EBV causes Multiple Sclerosis. Evidence indicating that EBV drives MS is growing. If EBV drives MS then elimination of EBV would be a rational therapy. There are licensed drugs with activity against EBV, such as the antiviral tenofovir alafenamide. #multiplesclerosis #ms #ebv
art4ms.com
See the following dropbox link for a number of scientific papers indicating that EBV is the cause and driver of MS disease activity, and on potential antiviral therapies. #MS #EBV #multiplesclerosis
www.dropbox.com/scl/fo/1qutc...
Discoveries beyond molecular mimicry describe how EBV drives multiple sclerosis
www.dropbox.com/scl/fi/ueqii...
Myelin antigen capture in the CNS by B cells expressing EBV latent membrane protein 1 leads to demyelinating lesion formation
www.cell.com/cell/fulltex...
Anoctamin-2-specific T cells link Epstein-Barr virus to multiple sclerosis
www.cell.com/cell/fulltex...
3 new reports on the mechanistic underpinnings of multiple sclerosis and Epstein-Barr virus involvement published in Cell
EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation
www.cell.com/cell/fulltex...
The authors of this paper created a list of therapies with anti-EBV effects.
Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach
pubmed.ncbi.nlm.nih.gov/39792343/
#ebv #ms #multiplesclerosis #ebvcausesmsn#art4ms
Broader Epstein–Barr virus–specific T cell receptor repertoire in patients with multiple sclerosis #ebv #ms #multiplesclerosis #ART4MS #EBVcausesMS
rupress.org/jem/article-...
#MultipleSclerosis is caused by #EBV. The risk of #MS increased 32-fold after infection with EBV. Serum levels of neurofilament light chain increased only after EBV infection. These findings suggest EBV as the leading cause of MS.
www.science.org/doi/10.1126/...
EBV as the “gluten of MS” hypothesis provides a rationale for trialing antiviral therapies #EBV #MS #multiplesclerosis #EBVcausesMS #ART4MS
www.msard-journal.com/article/S221...
The case for targeting latent and lytic
Epstein-Barr virus infection in multiple sclerosis #ms #ebv #ebvcausesms #multiplesclerosis #art4ms
pmc.ncbi.nlm.nih.gov/articles/PMC...
There is a reduced risk of developing MS in HIV+ patients taking antiretroviral therapy. There are also several cases of patients who presented indefinite remission or resolution of multiple sclerosis symptoms after induction of ART.
#ms #ebv #multiplesclerosis
link.springer.com/article/10.1...
In the era of antiviral trials for multiple sclerosis the answer lies in the details
#ebv #ms #multiplesclerosis #art4ms #antiviral
www.dropbox.com/scl/fo/1qutc...
Radiologic and clinical stability in an HIV-negative multiple sclerosis patient after #tenofovir: An updated case report
#MultipleSclerosis #MS #EBV
www.dropbox.com/scl/fo/1qutc...
HIV infection and multiple sclerosis: a case with unexpected “no evidence of disease activity” status #multiplesclerosis #ms #antiviral #ebv #antiretroviral #taf #tenofovir
journals.sagepub.com/doi/full/10....
Tenofovir as a treatment option for multiple sclerosis
www.sciencedirect.com/science/arti...
#MS #EBV #MultipleSclerosis
This indicates that the standard dose of TAF may be lower than optimal for EBV, as the EC90 is a typical therapeutic target. This data comes from an in vitro assay and the optimal dose needs to be determined in humans.
#MS_Selfie Newsletter - Necessary, but insufficient
Getting naysayers to understand and accept “EBV is necessary, but insufficient to develop MS” is important, as they often review and reject grant applications. And ..... => buff.ly/8rCPzQJ
Tenofovir prodrugs potently inhibit Epstein–Barr virus lytic DNA replication by targeting the viral DNA polymerase
#EBV #MS #MultipleSclerosis #antivirals #ARTMS #ART4MS
www.pnas.org/doi/10.1073/...
The below chart has important implications regarding TAF dose. Fig 5G indicates that the standard dose of TAF would reach a concentration needed to block 40% of DNA replication (EC40) mediated by the EBV polymerase after 40 min in their in vitro assay.
www.pnas.org/doi/10.1073/...
#ms #ebv
Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF), are both tenofovir prodrugs that improve the absorption and delivery of tenofovir, which gets converted into its active form inside cells to stop viral replication #multiplesclerosis #ebv #ms
www.descovyhcp.com/taf-pharmaco...
TAF is a newer generation prodrug designed for better tissue targeting, allowing for lower doses. A 25mg dose of TAF leads to higher tenofovir concentrations in lymphocytes compared to a 300mg dose of TDF.
Tenofovir disoproxil fumerate TDF at 300mg daily has been used for PrEP for over a decade. This may indicate that doses of tenofovir alafenamide fumerate TAF greater than 25mg are safe long term, however this needs further study. #PrEP #MultipleSclerosis #EBV
Below are clinical trials looking at tenofovir for treatment of Multiple Sclerosis. #EBV #antiretroviral #MS #antiviral art4ms.com
clinicaltrials.gov/study/NCT059...
mstrials.org.au/fatigue-in-r...
www.helse-bergen.no/en/neuro-sys...
EBV causes Multiple Sclerosis. Evidence indicating that EBV drives MS is growing. If EBV is drives MS then elimination of EBV would be a rational therapy. There are licensed drugs with activity against EBV, such as the antiviral tenofovir alafenamide. #multiplesclerosis #ms #ebv
art4ms.com